Dang C - Search Results

1

Dose-dense doxorubicin and cyclophosphamide followed by weekly paclitaxel with trastuzumab and lapatinib in HER2/neu-overexpressed/amplified breast cancer is not feasible because of excessive diarrhea.

Dang C, Lin N, Moy B, Come S, Sugarman S, Morris P, Abbruzzi A, Chen C, Steingart R, Patil S, Norton L, Winer E, Hudis C. Dang C, et al. J Clin Oncol. 2010 Jun 20;28(18):2982-8. doi: 10.1200/JCO.2009.26.5900. Epub 2010 May 17. J Clin Oncol. 2010. PMID: 20479410 Free PMC article. Clinical Trial.

2

Potential role of selective COX-2 inhibitors in cancer management.

Dang CT, Shapiro CL, Hudis CA. Dang CT, et al. Oncology (Williston Park). 2002 May;16(5 Suppl 4):30-6. Oncology (Williston Park). 2002. PMID: 12102578 Free article. Review.

3

Dose-dense treatment prolongs disease-free survival of women with node positive breast cancer.

Dang C, Seidman AD. Dang C, et al. Cancer Treat Rev. 2003 Oct;29(5):453-6. doi: 10.1016/s0305-7372(03)00164-6. Cancer Treat Rev. 2003. PMID: 12972365 No abstract available.

4

Risk models for neutropenia in patients with breast cancer.

Dang CT, Fornier MN, Hudis CA. Dang CT, et al. Oncology (Williston Park). 2003 Nov;17(11 Suppl 11):14-20. Oncology (Williston Park). 2003. PMID: 14682114 Free article. Review.

5

Phase II study of celecoxib and trastuzumab in metastatic breast cancer patients who have progressed after prior trastuzumab-based treatments.

Dang CT, Dannenberg AJ, Subbaramaiah K, Dickler MN, Moasser MM, Seidman AD, D'Andrea GM, Theodoulou M, Panageas KS, Norton L, Hudis CA. Dang CT, et al. Clin Cancer Res. 2004 Jun 15;10(12 Pt 1):4062-7. doi: 10.1158/1078-0432.CCR-03-0463. Clin Cancer Res. 2004. PMID: 15217939 Clinical Trial.

6

Phase II study of feasibility of dose-dense FEC followed by alternating weekly taxanes in high-risk, four or more node-positive breast cancer.

Dang CT, D'Andrea GM, Moynahan ME, Dickler MN, Seidman AD, Fornier M, Robson ME, Theodoulou M, Lake D, Currie VE, Hurria A, Panageas KS, Norton L, Hudis CA. Dang CT, et al. Clin Cancer Res. 2004 Sep 1;10(17):5754-61. doi: 10.1158/1078-0432.CCR-04-0634. Clin Cancer Res. 2004. PMID: 15355903 Clinical Trial.

7

Adjuvant therapy for breast cancer: practical lessons from the early breast cancer trialists' collaborative group.

Hudis CA, Dang CT. Hudis CA, et al. Breast Dis. 2004;21:3-13. doi: 10.3233/bd-2004-21102. Breast Dis. 2004. PMID: 15687717 Review. No abstract available.

8

Effect of adjuvant breast cancer chemotherapy on cognitive function from the older patient's perspective.

Hurria A, Goldfarb S, Rosen C, Holland J, Zuckerman E, Lachs MS, Witmer M, van Gorp WG, Fornier M, D'Andrea G, Moasser M, Dang C, Van Poznak C, Robson M, Currie VE, Theodoulou M, Norton L, Hudis C. Hurria A, et al. Among authors: dang c. Breast Cancer Res Treat. 2006 Aug;98(3):343-8. doi: 10.1007/s10549-006-9171-6. Epub 2006 Mar 16. Breast Cancer Res Treat. 2006. PMID: 16541322

9

Adjuvant taxanes in the treatment of breast cancer: no longer at the tip of the iceberg.

Dang C, Hudis C. Dang C, et al. Clin Breast Cancer. 2006 Apr;7(1):51-8. doi: 10.3816/CBC.2006.n.013. Clin Breast Cancer. 2006. PMID: 16764744 Review.

10

Can granulocyte-colony stimulating factor worsen anemia?

Dang C, Hudis C. Dang C, et al. J Clin Oncol. 2006 Jul 1;24(19):2985-6. doi: 10.1200/JCO.2006.06.1416. Epub 2006 Jun 12. J Clin Oncol. 2006. PMID: 16769981 No abstract available.

Save citations to file

Email citations

Send citations to clipboard

Add to Collections

Add to My Bibliography

Create a file for external citation management software

Your saved search

Your RSS Feed

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Article Language

Species

Sex

Age

Other

1,385 results

Search Page

Filters